Free Trial
NASDAQ:PGNY

Progyny (PGNY) Stock Price, News & Analysis

Progyny logo
$19.49 -0.01 (-0.05%)
Closing price 10/24/2025 04:00 PM Eastern
Extended Trading
$19.35 -0.14 (-0.72%)
As of 10/24/2025 07:58 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Progyny Stock (NASDAQ:PGNY)

Advanced

Key Stats

Today's Range
$19.27
$19.66
50-Day Range
$19.17
$23.78
52-Week Range
$13.39
$26.76
Volume
840,739 shs
Average Volume
1.75 million shs
Market Capitalization
$1.68 billion
P/E Ratio
33.03
Dividend Yield
N/A
Price Target
$25.44
Consensus Rating
Moderate Buy

Company Overview

Progyny Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
70th Percentile Overall Score

PGNY MarketRank™: 

Progyny scored higher than 70% of companies evaluated by MarketBeat, and ranked 293rd out of 943 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Progyny has received a consensus rating of Moderate Buy. The company's average rating score is 2.70, and is based on 5 buy ratings, 4 hold ratings, and no sell ratings.

  • Upside Potential

    Progyny has a consensus price target of $25.44, representing about 30.6% upside from its current price of $19.49.

  • Amount of Analyst Coverage

    Progyny has only been the subject of 4 research reports in the past 90 days.

  • Read more about Progyny's stock forecast and price target.
  • Earnings Growth

    Earnings for Progyny are expected to grow by 8.33% in the coming year, from $0.60 to $0.65 per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Progyny is 33.03, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 39.83.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Progyny is 33.03, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 31.50.

  • Price to Earnings Growth Ratio

    Progyny has a PEG Ratio of 1.66. PEG Ratios above 1 indicate that a company could be overvalued.

  • Price to Book Value per Share Ratio

    Progyny has a P/B Ratio of 3.93. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

  • Read more about Progyny's valuation and earnings.
  • Percentage of Shares Shorted

    9.81% of the float of Progyny has been sold short.
  • Short Interest Ratio / Days to Cover

    Progyny has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Progyny has recently increased by 2.47%, indicating that investor sentiment is decreasing.
  • Dividend Yield

    Progyny does not currently pay a dividend.

  • Dividend Growth

    Progyny does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    9.81% of the float of Progyny has been sold short.
  • Short Interest Ratio / Days to Cover

    Progyny has a short interest ratio ("days to cover") of 6.5.
  • Change versus previous month

    Short interest in Progyny has recently increased by 2.47%, indicating that investor sentiment is decreasing.
  • News Sentiment

    Progyny has a news sentiment score of 0.80. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.93 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 11 news articles for Progyny this week, compared to 8 articles on an average week.
  • Search Interest

    7 people have searched for PGNY on MarketBeat in the last 30 days. This is an increase of 133% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Progyny to their MarketBeat watchlist in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Progyny insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $179,311.00 in company stock.

  • Percentage Held by Insiders

    Only 9.40% of the stock of Progyny is held by insiders.

  • Percentage Held by Institutions

    94.93% of the stock of Progyny is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Progyny's insider trading history.
Receive PGNY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Progyny and its competitors with MarketBeat's FREE daily newsletter.

By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

PGNY Stock News Headlines

$100 Trillion “AI Metal” Found in American Ghost Town
Jeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could be the biggest technology story of this decade. In short, he believes what he's holding in his hand is the key to the $100 trillion AI boom… And only one company here in the U.S. can mine this obscure metal.tc pixel
Comparing Progyny (NASDAQ:PGNY) and Ryman Healthcare (OTCMKTS:RYHTY)
Canaccord Genuity Reaffirms Their Hold Rating on Progyny (PGNY)
See More Headlines

PGNY Stock Analysis - Frequently Asked Questions

Progyny's stock was trading at $17.25 at the beginning of 2025. Since then, PGNY shares have increased by 13.0% and is now trading at $19.49.

Progyny, Inc. (NASDAQ:PGNY) released its earnings results on Thursday, August, 7th. The company reported $0.19 earnings per share for the quarter, missing analysts' consensus estimates of $0.42 by $0.23. Progyny's quarterly revenue was up 9.5% compared to the same quarter last year.
Read the conference call transcript
.

Progyny (PGNY) raised $150 million in an IPO on Friday, October 25th 2019. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P. Morgan, Goldman Sachs and BofA Merrill Lynch acted as the underwriters for the IPO and Citigroup, Piper Jaffray, SVB Leerink and TPG Capital were co-managers.

Top institutional shareholders of Progyny include Fort Washington Investment Advisors Inc. OH (1.93%), Pacer Advisors Inc. (0.45%), Voya Investment Management LLC (0.28%) and State of Alaska Department of Revenue (0.05%). Insiders that own company stock include Tpg Gp A, Llc, Peter Anevski, Michael E Sturmer, Norman Payson, David J Schlanger, Allison Swartz, Mark S Livingston, Cheryl Scott and Kevin K Gordon.
View institutional ownership trends
.

Shares of PGNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Progyny investors own include Humana (HUM), American Water Works (AWK), NVIDIA (NVDA), Rambus (RMBS), Voyager Therapeutics (VYGR), Saia (SAIA) and Waste Connections (WCN).

Company Calendar

Last Earnings
8/07/2025
Today
10/25/2025
Next Earnings (Estimated)
11/06/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Medical Services
Sub-Industry
Healthcare
Current Symbol
NASDAQ:PGNY
CIK
1551306
Fax
N/A
Employees
310
Year Founded
2008

Price Target and Rating

High Price Target
$28.00
Low Price Target
$17.00
Potential Upside/Downside
+30.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

EPS (Trailing Twelve Months)
$0.59
Trailing P/E Ratio
33.03
Forward P/E Ratio
32.48
P/E Growth
1.66
Net Income
$54.34 million
Net Margins
4.28%
Pretax Margin
7.18%
Return on Equity
10.69%
Return on Assets
7.12%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
2.70
Quick Ratio
2.70

Sales & Book Value

Annual Sales
$1.24 billion
Price / Sales
1.35
Cash Flow
$0.34 per share
Price / Cash Flow
56.51
Book Value
$4.96 per share
Price / Book
3.93

Miscellaneous

Outstanding Shares
85,982,000
Free Float
77,900,000
Market Cap
$1.68 billion
Optionable
Optionable
Beta
1.34

Social Links

10 Best Stocks to Own: Fall 2025 Cover

Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

This page (NASDAQ:PGNY) was last updated on 10/25/2025 by MarketBeat.com Staff
From Our Partners